3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
8
Lymphoma
7
Lymphoma, Non-Hodgkin
6
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Follicular
5
Recurrence
3
Neoplasms
2
Leukemia, B-Cell
2
Burkitt Lymphoma
2
Neoplasm, Residual
1
Mature B-Cell Malignancies
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lymphatic Diseases
1
Leukemia, Hairy Cell
1
Heart Failure
1
Dendritic Cell Sarcoma, Interdigitating
1
Cytokine Release Syndrome
1
Interventions
fludarabine phosphate
2
fludarabine
2
blinatumomab
2
Cyclophosphamide
2
tislelizumab
1
tisagenlecleucel
1
obinutuzumab
1
Radiotherapy
1
Monatide (IMS 3015)
1
HMPL-013
1
Cetuximab
1
Blood Specimen Collection
1
Biological Assay
1
AP 1903 reagent
1
ALT-803
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
obinutuzumab
×
30 days
×
Clear all
NCT05929222
2026-06-01
FIL_GAZEBO
Fondazione Italiana Linfomi - ETS
Phase 3
Recruiting
190 enrolled